News

COVID-19 has further highlighted the need for innovative models that minimize face-to-face contact in HCV treatment.

ViiV Healthcare’s investigational therapy, GSK’254, demonstrated antiviral activity, safety, and tolerability in its phase 2a proof-of-concept findings.

Convalescent plasma treatment was found not to improve survival or disease course in the patient group.

A UK health authority representative discussed the possibility of a fall season booster to prevent another winter surge of cases.

Gut microbiome is known to release enzymes that degrade plasma glycans which regulate inflammation.

With the highest HIV incidence rate in this part of the country, the need to get people from diagnosis to timely antiretroviral therapy (ART) remains an urgent need.

New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.

Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.

Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.

Increased hospitalization risk was driven mainly by the high burden of comorbidities in both groups.

Change was associated with risk factors that have not been reported like chronic lung disease.

Merck’s islatravir subdermal implant demonstrated it achieved active drug concentrations above the pre-specified pharmacokinetics (pk) threshold at 12 weeks across three doses.

People with HIV had similar control of most conditions except for triglycerides.

Though small in scale and still cautious, the new advisory reflects confidence in SARS-CoV-2 mitigation among a more vaccinated population.

Investigators examined outcomes of privileged US citizens and compared them to those health outcomes of average residents in other developed countries.

While the world’s focus remains on COVID-19, beyond this ongoing crisis lingers another that requires leadership, innovation, and collaboration from policy makers, the health care community, and the private sector.

Windtree Therapeutics is in a phase 2 clinical trial for its investigational therapy, Lucinactant, which produces a synthetic surfactant being studied for acute lung injury in patients with COVID-19 and acute respiratory distress syndrome (ARDS).

A discussion on the pros and cons of frequent, rapid testing in the community.

Cue Health's test is over the counter (OTC) and can be utilized at home.

Hyper-induction of pro-inflammatory cytokines is one of the key aspects of SARS-CoV-2.

Molecular tools like RNA-activated RNases could be a potential new paradigm for therapeutics.

The Luminex test will be able to detect influenza and COVID-19.

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

By integrating genomic and temporal data, 409 viral clusters within 292 care homes were identified.

Neurotropic capacities of SARS-CoV-2 makes it a potent factor to cause acute and late neurological effects.

The findings underscore the connection between COVID-19 and the increased risk from obesity.

Investigators have discovered active substances that can block the replication of coronavirus and may create a pathway for new therapies.

A review of emergency room records showed a very small percentage of patients had acute ischemic strokes, but for those who did, there was an increased risk of requiring long-term care after hospital discharge.